Background
==========

Trisomy 21 is the most common chromosomal anomaly worldwide, affecting about 1 in 700 newborns \[[@B1]\]. These individuals typically have low resting metabolic rates \[[@B2]\] and are particularly susceptible to infections \[[@B3]\] and hypothyroidism \[[@B4]\]. Moreover, defects in the inner mitochondrial membrane potential \[[@B5]\] and mitochondrial respiratory chain enzymes are documented in these patients \[[@B6],[@B7]\]. Mitochondrial disturbances, increased oxidative stress and apoptosis have been described in the neurons, predisposing to precocious Alzheimer's disease \[[@B8]\]. Alterations in metabolic enzymes (e.g., monoamine oxidase-B, cytochrome oxidase, isocitrate dehydrogenase and glutamate dehydrogenase) have been also linked to impaired energy metabolism in trisomy 21 children \[[@B9]\]. Calcium levels are lower than in control children, which may alter cellular signaling \[[@B10]\].

Increased congenital heart disease and other major anomalies are exceptionally frequent in children with trisomy 21. It is not known whether these defects are linked to the biological impairments described above.

The use of the phosphorescence oxygen analyzer to measure lymphocyte respiration was recently reported. Lymphocytes were shown to be suitable for screening of certain mitochondrial disorders \[[@B11]\]. These methodologies were used to measure lymphocyte respiration rates in children with trisomy 21 and compare them with rates in children without this disorder.

Methods
=======

Reagents and solutions
----------------------

Pd (II) complex of *meso*-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin was purchased from Porphyrin Products (Logan, UT). Glucose oxidase (powder from *Aspergillus niger),* D (+) glucose anhydrous, Histopaque-1077 and remaining reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Pd phosphor solution (2.5 mg/ml = 2 mM) was prepared in distilled water (dH~2~O) and stored at −20°C. Glucose oxidase solution was prepared in dH~2~O (10 mg/mL) and stored at −20°C. Sodium cyanide (NaCN) solution (1.0 M) was prepared in dH~2~O; the *p*H was adjusted to \~7.0 with 12N HCl and stored at −20°C. Phosphate-buffered saline (PBS) containing glucose (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na~2~HPO~4~, 1.4 mM KH~2~PO~4~ and 10 mM glucose; *p*H 7.4) was stored at 4°C.

Subjects
--------

Venous blood samples (5 to 8 mL) were collected in heparin tubes and processed in \<2 hr for peripheral blood mononuclear cell (PBMC) isolation and O~2~ measurement. Blood was also collected from age- and gender-matched healthy controls. All trisomy 21 participants attended the outpatient facilities at Tawam and Al Ain Hospitals (Al Ain city, Abu Dhabi) for routine visits. All control participants were healthy children who had no medical complaints.

The study was approved by the institutional review board for protection of human subjects. Informed consent was obtained for each participating subject.

PBMC isolation
--------------

Plasma was collected from blood samples by centrifugation and possessed for Comprehensive Metabolic Panel and lipid profile. The samples were then diluted with equal volume of phosphate-buffered saline (PBS) containing 10 mM glucose and gently layered on the top of 10 mL Histopaque-1077. The mixtures were centrifuged at 15°C, 400 x*g* for 30 min. Collected PBMC were diluted with the same solution and re-centrifuged as above. The pellets were suspended in PBS, 10 mM glucose, 3 μM Pd phosphor and 0.5% fat-free bovine serum albumin for O~2~ measurements at 37°C. Cell count and viability were determined by light microscopy, using a hemocytometer under standard trypan blue staining conditions. Only trypan blue-negative cells (\>95%) were counted.

Oxygen instrument
-----------------

A phosphorescence oxygen analyzer that measures dissolved O~2~ in solutions as function of time was used to determine the rate of PBMC respiration \[[@B12],[@B13]\]. This method is based on the principle that O~2~ quenches the phosphorescence of a palladium phosphor \[[@B14]\].

The Pd (II) derivative of *meso*-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin had an absorption maximum at 625 nm and a phosphorescence emission maximum at 800 nm. Samples were exposed to light flashes (10 per sec) from a pulsed light-emitting diode array with a peak output at 625 nm. Emitted phosphorescent light was detected by a Hamamatsu photomultiplier tube after first passing it through a wide-band interference filter centered at 800 nm. Amplified phosphorescence was digitized at 1--2 MHz using an analog/digital converter (PCI-DAS 4020/12 I/O Board) with 1 to 20 MHz outputs.

The phosphorescence decay rate (1/τ) was characterized by a single exponential; I = Ae^-*t*/τ^, where I = Pd phosphor phosphorescence intensity. The values of 1/τ were linear with dissolved O~2~: 1/τ = 1/τ^o^ + *k*~*q*~\[O~2~, where 1/τ = the phosphorescence decay rate in the presence of O~2~, 1/τ^o^ = the phosphorescence decay rate in the absence of O~2~, and *k*~q~ = the second-order O~2~ quenching rate constant in sec^-1^ μM^-1^ (14). For calibration, the reaction contained PBS, 3 μM Pd phosphor, 0.5% fat-free albumin, 50 μg/mL glucose oxidase and various concentrations of β-glucose \[[@B11]\].

Cellular respiration was measured at 37°C in 1.0-mL sealed vials. Mixing was carried out with the aid of parylene-coated stirring bars. The respiratory substrates were endogenous metabolic fuels supplemented with glucose.

Statistical analysis
--------------------

The data are summarized by arithmetic mean and standard deviation. Mann--Whitney *U* test was used for nonparametric values. *P*\<0.05 was considered significant.

Results
=======

In cell suspensions sealed from air, \[O~2~\] decreased linearly with time, indicating the kinetics of mitochondrial O~2~ consumption was zero-order. The rate of respiration (*k*, in μM O~2~/min) was thus the negative of the slope d\[O~2~\]/d*t*. Cyanide markedly inhibited respiration (≥96%), confirming O~2~ was consumed mainly by the mitochondrial respiratory chain.

Lymphocyte respiration was measured in 26 children with trisomy 21 and 26 control children. Representative O~2~ runs are shown in Figure  [1a](#F1){ref-type="fig"}-b. For trisomy 21 children, the rate of respiration (*k*~*c*~, in μM O~2~ per min per 10^7^ cells, mean ± SD, n = 26) was 0.82 ± 0.62 (median = 0.60; range = 0.20 to 2.80), Table  [1](#T1){ref-type="table"}. The values of *k*~*c*~ for control children (n = 26) were 1.36 ± 0.79 (median = 1.17; range = 0.60 to 3.12; -2SD = 0.61). The *p* value for *k*~*c*~ between trisomy 21 and control children was \<0.001, Figure  [2](#F2){ref-type="fig"}. Similar results with higher significance (*p*\<0.000) were obtained after excluding the five children with trisomy 21 and elevated serum TSH (values \>6.1 mU/L). Fourteen of 26 (54%) children with trisomy 21 had *k*~*c*~ values of 0.20 to 0.60 (\<−2SD).

![**Representative O**~**2**~**runs for lymphocyte respiration in a 15-year-old male with trisomy 21 (Panel a, Subject 8 in Table**[1](#T1){ref-type="table"}**) and control subject (Panel b).** The lines are best linear fits (*R*^2^ \>0.830). The additions of 10 mM NaCN and 50 μg/mL glucose oxidase are shown.](1471-2431-12-193-1){#F1}

###### 

Rates of lymphocyte respiration, thyroid function and clinical findings in trisomy 21 children

  **Children No.**   **Age (yr)**   **Gender**   **BMI (kg/m**^**2**^**)**   ***k***~***c***~**(μM O**~**2**~**min**^**-1**^**per 10**^**7**^**cells)**   **TSH (mIU/L)**   **Free T4 (pmol/L)**   **Clinical status**
  ------------------ -------------- ------------ --------------------------- ---------------------------------------------------------------------------- ----------------- ---------------------- ----------------------------------------
  1                  1.5            F            12.8                        1.6                                                                          3.5               20.7                   AVSD
  2                  5              M            16.1                        2.0                                                                          1.6               14.7                   celiac disease
  3                  17             M            28.6                        1.2                                                                          4.9               9.5                    normal
  4                  12             M            16.3                        0.6                                                                          2.6               10                     AVSD
  5                  12             F            30.8                        1.2                                                                          3.8               13.2                   VSD
  6                  9              M            17.1                        0.6                                                                          2.6               NA                     bronchial asthma
  7^\*^              15             M            30.2                        0.6                                                                          2.8               10.0                   aortic stenosis, hypothyroidism
  8                  15             M            44.3                        2.8                                                                          13.2              11.0                   Moya Moya disease, hypothyroidism
  9                  3              F            13.8                        0.4                                                                          3.7               14.2                   bronchial asthma
  10                 2              F            15.2                        0.6                                                                          5.3               13.0                   obstructive sleep apnea, low vitamin D
  11                 3              M            14.5                        0.5                                                                          2.9               15.8                   ASD, PDA
  12                 5              M            17.5                        0.9                                                                          2.6               9.9                    VSD
  13^\*^             4              M            15.7                        0.2                                                                          12.6              11.6                   hypothyroidism
  14                 10             F            NA                          0.8                                                                          5.1               10.4                   normal
  15                 6              M            18.7                        0.4                                                                          5.1               10.5                   normal
  16                 4              M            14.8                        1.2                                                                          3.6               11.9                   normal
  17                 9              F            16                          0.7                                                                          3.9               10.7                   normal
  18                 1.5            M            16.3                        1.5                                                                          11.6              11.9                   hypothyroidism
  19                 5              M            NA                          1.0                                                                          2.9               11.1                   normal
  20                 6              M            20.7                        0.3                                                                          3.9               10.4                   normal
  21                 8              M            31.4                        0.4                                                                          5.1               10.5                   asthma, myelomeningocele
  22                 2              F            14.3                        0.3                                                                          7.7               11.2                   normal
  23                 7              F            17.8                        0.3                                                                          1.3               9.3                    normal
  24                 8              F            23.2                        0.2                                                                          3.7               11.3                   AVSD
  25                 6              M            35.1                        0.2                                                                          3.6               14.1                   AVSD
  26                 4              M            13.6                        0.7                                                                          6.4               14.1                   normal
  mean ± SD (CV)     6.9 ± 4.4                   20.6 ± 8.3 (40%)            0.82 ± 0.62 (76%)                                                            4.8 ± 3.1         12.0 ± 2.5              

AVSD, atrioventricular septal defect; VSD, ventricular septal defect; ASD, atrial septal defect; PDA, patent ductus arteriosus; CV, coefficient of variation. NA, not available.

In normal 2 to7 year-old children, the TSH values are 0.10 to 5.9 mU/L (mean = 2.2 mU/L); in normal 9 to 16 year-old children, the TSH values are 0.20 to 6.1 mU/L (mean = 2.3 mU/L).

Reference ranges for free T4 are 11.0 to 22.6 pmol/L in children 1 to 5 years of age, 11.6 to 21.5 pmol/L in children 6 to 10 years of age, and 12.0 to 20.6 pmol/L in children 11 to 19 years of age ( <https://www.labcorp.com/wps/portal/provider>).

\* On thyroxin prior to O~2~ consumption testing.

![**Lymphocyte respiration in 26 children with trisomy 21 and 26 control children.** The horizontal lines are mean values.](1471-2431-12-193-2){#F2}

In children with trisomy 21 and normal TSH (n = 21), the *k*~*c*~ value did not correlate with the TSH level (*R*^*2*^ \>0.072, Figure  [3a](#F3){ref-type="fig"}). By contrast, in children with trisomy 21 and abnormal lymphocyte respiration (*k*~*c*~ \< 0.61, n = 14), the *k*~*c*~ value correlated with the TSH level (*R*^*2*^ \>0.225, *R* \>0.474, Figure  [3b](#F3){ref-type="fig"}).

![**Lymphocyte respiration in children with trisomy 21 as a function of serum TSH.*Panel a:*** Circles, children (n = 21) with trisomy 21 and normal TSH (levels ≤5.3 mU/L; line is the best linear fit, *R*^2^ \> 0.0727); diamonds, children (n = 5) with trisomy 21 and elevated TSH (levels 7.7 to 13.2 mU/L). ***Panel b:*** Children (n = 14) with trisomy 21 and abnormal (low) rate of respiration (*k*~*c*~ \< 0.60 μM O~2~ per min per 10^7^ cells). The horizontal line reflects upper limit of normal TSH (\<6.1 mU/L, please see footnote to Table  [1](#T1){ref-type="table"}).](1471-2431-12-193-3){#F3}

Five children with trisomy 21 had elevated TSH levels (\>6.1 mIU/L). Their median TSH was 12.6 mIU/L (range, 6.4 to 13.2) and median *k*~*c*~ was 0.7 μM O~2~ per min per 10^7^ cells (range, 0.2 to 2.8). Subject 8 (15-year-old adolescent male) had a TSH level of 13.2 mIU/L and a *k*~*c*~ values of 2.8 μM O~2~ per min per 10^7^ cells (Table  [1](#T1){ref-type="table"} and Figure  [1a](#F1){ref-type="fig"}).

There were 8 children with trisomy 21 and congenital heart disease. Their median *k*~*c*~ value was 0.6 μM O~2~ per min per 10^7^ cells (range, 0.2 to 1.6), and did not significantly differ from the remaining children (*p* = 0.238).

In children with trisomy 21, the *k*~*c*~ positively correlated with BMI (*R* \>0.302, Figure  [4a](#F4){ref-type="fig"}), serum creatinine (*R* \>0.507), BUN (*R* \>0.535) and albumin (*R* \>0.446, Figure  [4b](#F4){ref-type="fig"}), Table  [2](#T2){ref-type="table"}.

![**BMI (Panel a) and serum albumin (Panel b) as a function of rates of lymphocyte respiration (*k***~***c***~**) in trisomy 21 children.**](1471-2431-12-193-4){#F4}

###### 

**Correlations (*R*) between serum metabolic parameters and rates of lymphocyte respiration in trisomy 21 (n = 23) and control (n = 25) children**^**\***^

                                                                                                      **Rate of respiration (*kc*)**
  ------------ ------- ------- -------- -------- -------- ------- -------- -------- -------- -------- --------------------------------
  Trisomy 21   0.507   0.535   0.446    0.508    0.137    0.048   0.007    0.091    0.145    0.092    0.170
  Control      0.192   0.037   −0.146   −0.091   −0.136   0.112   −0.009   −0.060   −0.080   −0.024   −0.057

\* Serum was not available in 3 patients and 1 control.

Discussion
==========

The rates of lymphocyte respiration in the children with trisomy 21 were slower than in the control group (Figure  [2](#F2){ref-type="fig"}). These differences could reflect a relatively lower rate of mitochondrial energy conversion in trisomy 21 children that may be linked to some pathological findings pertinent to this disorder, such as defects in the inner mitochondrial membrane \[[@B5],[@B8]\].

The mechanism for slower rates of lymphocyte respiration in children with trisomy 21 could be multi-factorial. For example, the thyroid hormone is a well known regulator of the rate of metabolism; and hypothyroidism is common in children with trisomy 21. As shown in Figure  [3b](#F3){ref-type="fig"}, high TSH (low or ineffective thyroxin) may contribute to the slower lymphocyte respiration in some children. Thus, thyroxin replacement is expected to improve lymphocyte respiration in those with hypothyroidism.

Of note, normal TSH values for children 2 to 7 years of age are 0.10 to 5.9 mU/L (mean = 2.2 mU/L) and for children 9 to 16 years of age are 0.20 to 6.1 mU/L (mean = 2.3 mU/L). Using these cutoffs, lymphocyte respiration was found to be higher in euthyroid trisomy 21 children than those with hypothyroidism.

Body-mass index, protein metabolism (BUN, total protein and albumin), and serum creatinine positively correlated with rates of lymphocyte respiration, but only in trisomy 21 children (Table  [2](#T2){ref-type="table"} and Figure  [4a](#F4){ref-type="fig"}-b). As previously reported, protein metabolism (proteolysis, oxidation and synthesis) is linked to obesity \[[@B15],[@B16]\], a finding that is common in children with trisomy 21.

Close correlations were documented between cerebral O~2~ consumptions and mental function, including depression and dementia \[[@B17],[@B18]\]. It is unknown if our finding of slower lymphocyte respiration in trisomy 21 children is applicable to other organs. Nevertheless, our findings are consistent with the recent reports on mitochondrial disturbances in those with trisomy 21 \[[@B19]-[@B23]\]. Decreased basal 3\'-5\'-cyclic adenosine monophosphate, increased reactive oxygen species and impaired NADH:ubiquinone reductase (complex I of the respiratory chain) were noted in fibroblasts from those with trisomy 21 \[[@B20]\].

Limitations of the study
------------------------

No study was found in the literature that addressed lymphocyte respiration in children with trisomy 21. Additional studies are needed in a larger population.

Conclusions
===========

Children with trisomy 21 in this study have lower lymphocyte bioenergetics, a finding that is consistent with the known mitochondrial disturbances in these children. The clinical significance implication of this finding requires further studies.
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